drugset / Trial / NCT00627679
Safety and Blood Level Study of Unit Dose Budesonide
Phase 1
Completed
16 enrolled
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan · collabQ-Pharm Pty Limited · collab
RandomizedCrossoverTriple-blindTreatment
Summary
The purpose of this study is to evaluate the tolerability and pharmacokinetics of three doses of MAP0010 (Unit Dose Budesonide) compared with Pulmicort Respules® (Budesonide) in healthy volunteers.
Timeline
- Start
- 2005-12
- Primary completion
- 2005-12
- Completion
- 2006-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | — | Other |